Merck's Welireg combo fails in first-line kidney cancer

Adding Merck’s Welireg to an existing Keytruda regimen didn’t lead to a significant improvement in newly diagnosed patients with advanced kidney cancer, Merck announced on Tuesday. The results mark a setback ...